Plasma-Derived Circulating Tumor DNA in Patients with Advanced EGFR-Positive Exon 20 NSCLC Treated With Osimertinib

被引：0
|
作者：
Zwierenga, F. [1 ]
Muntinghe-Wagenaar, B. [1 ]
Rozendal, P. [1 ]
van der Leest, P. [1 ]
Schuuring, E. [1 ]
van der Wekken, A. J. [1 ]
机构：
[1] Univ Med Ctr Groningen, Groningen, Netherlands
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期
关键词：
ctDNA; EGFR exon 20; resistance;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP.06D.02
引用
收藏
页码：S502 / S502
页数：1
相关论文
共 50 条
  • [41] Comment on: 'Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer'
    Inagaki, Yuji
    Tamiya, Akihiro
    LUNG CANCER, 2020, 148 : 179 - 180
  • [42] Predictive Value of Circulating Tumor Cells and Circulating Free DNA in NSCLC Patients Treated with Nivolumab
    Rossi, G.
    Tagliamento, M.
    Alama, A.
    Coco, S.
    Genova, C.
    Rijavec, E.
    Barletta, G.
    Biello, F.
    Vanni, I.
    Boccardo, S.
    Dal Bello, M. G.
    Alessandra, R.
    Fontana, V.
    Grossi, F.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S730 - S731
  • [43] Circulating tumor DNA (ctDNA) as predictive biomarker in NSCLC patients treated with nivolumab
    Passiglia, F.
    Perez, A.
    Listi, A.
    Castiglia, M.
    Musso, E.
    Ancona, C.
    Rizzo, S.
    Alu, M.
    Blasi, L.
    Russo, A.
    ANNALS OF ONCOLOGY, 2017, 28
  • [44] Urinary circulating DNA detection for dynamic tracking of EGFR mutations for NSCLC patients treated with EGFR-TKIs
    Chen, S.
    Zhao, J.
    Cui, L.
    Liu, Y.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2017, 19 (03): : 332 - 340
  • [45] Urinary circulating DNA detection for dynamic tracking of EGFR mutations for NSCLC patients treated with EGFR-TKIs
    S. Chen
    J. Zhao
    L. Cui
    Y. Liu
    Clinical and Translational Oncology, 2017, 19 : 332 - 340
  • [46] Serial Circulating Tumor DNA (ctDNA) Analysis of Blood and Saliva Predicts Osimertinib Response and Resistance in EGFR-Mutant NSCLC
    Kim, C.
    Xi, L.
    Cultraro, C.
    Wei, F.
    Cheng, J.
    Shafiei, A.
    Pham, T.
    Roper, N.
    Akoth, E.
    Strom, C.
    Tu, M.
    Liao, W.
    Chia, D.
    Morris, C.
    Rajan, A.
    Bagheri, M.
    Jones, G.
    Wong, D.
    Raffeld, M.
    Guha, U.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S366 - S366
  • [47] Osimertinib Plasma Trough Concentration in Relation to Brain Metastases Development in Patients With Advanced EGFR-Mutated NSCLC
    Gulikers, Judith L.
    Veerman, G. D. Marijn
    Jebbink, Merel
    Kruithof, Paul D.
    Steendam, Christi M. J.
    Boosman, Rene J.
    Mathijssen, Ron H. J.
    Tjan-Heijnen, Vivianne C. G.
    Driessen, Johanna H. M.
    Dursun, Safiye
    Smit, Egbert F.
    Dingemans, Anne -Marie C.
    van Geel, Robin M. J. M.
    Croes, Sander
    Hendriks, Lizza E. L.
    JTO CLINICAL AND RESEARCH REPORTS, 2024, 5 (04):
  • [48] Clinical Outcomes in Advanced EGFR-Mutant NSCLC Patients Treated with First-Generation EGFR TKIs Followed by Subsequent Osimertinib
    Yao, Y.
    Cheng, J.
    Kang, J.
    Li, X.
    Chen, H.
    Zhou, Q.
    Xu, C.
    Zhang, X.
    Su, J.
    Yan, H.
    Wu, Y.
    Yang, J.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S671 - S671
  • [49] Tracking of activating EGFR mutations predicts progression-free survival in advanced EGFR-mutated NSCLC patients treated with osimertinib
    Buder, A.
    Hochmair, M. J.
    Setinek, U.
    Filipits, M.
    ANNALS OF ONCOLOGY, 2019, 30
  • [50] Dynamic Monitoring and Predictive Value of Circulating Tumor Cells in EGFR Mutant Advanced NSCLC Patients Treated with First-Line EGFR-TKIs
    Su, C.
    Jiang, T.
    Zhao, J.
    Li, X.
    Zhou, C.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S409 - S410
12345